Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy in Clozapine-Resistant Treatment-Refractory Schizophrenia
NCT03652974Phase 4Completed
- Sponsor
- Shanghai Mental Health Center
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of valproic acid and amisulpride in schizophrenia (4 arms), sponsored by Shanghai Mental Health Center. Primary endpoints: Positive and Negative Syndrome Scale at 12 weeks, Scale for the Assessment of Negative Symptoms at 12 weeks and 4 more. Started Sep 2018; status: completed.
02
Drugs
valproic acidamisulpride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03652974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652974.